tauroselcholic acid: clinical use

Prescribing considerations

• Use is diagnostic only; radiation exposure must be individually justified and kept as low as reasonably achievable.
• Confirm pregnancy status where relevant and review breastfeeding arrangements before administration.
• Paediatric use needs particular benefit–risk assessment because clinical experience is absent and effective radiation exposure is proportionally higher.
• The capsule contains sodium, which may matter for patients following a restricted-sodium diet.

Contraindications and cautions

• Hypersensitivity to tauroselcholic acid or any excipient.
• Use particular caution in severe hepatic dysfunction or biliary obstruction because hepatic radiation exposure may be substantially increased.

Monitoring

• Review medicines that may interfere with enterohepatic cycling, particularly bile acid sequestrants.
• Ensure completion of the locally specified acquisition protocol so retention can be interpreted reliably.
• Maintain facilities for immediate management of hypersensitivity or anaphylaxis.

Clinical pharmacology

A selenium-75-labelled bile acid analogue that follows enterohepatic circulation without a clinically relevant pharmacodynamic effect at diagnostic exposure. In people with normal absorption, it is taken up mainly in the terminal ileum; measured loss or reduced retention reflects impaired bile acid recycling.

Formulation and product differences

• The selected UK product is a hard gelatin radiopharmaceutical capsule for administration by authorised staff in a designated clinical setting.
• It contains disodium phosphate, gelatin, titanium dioxide, quinoline yellow and erythrosine, and has clinically relevant sodium content.
• No paediatric-specific formulation is available.